• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

FDA Approves Emergency Use Authorization for a 24-hour, Saliva Test for COVID-19

Share:

April 7, 2020

MicroGenDX Laboratories, the world leader in providing PCR and Next Generation DNA Sequencing in microbial identification, has validated a real-time Reverse Transcriptase PCR (rRT-PCR) assay for the specific detection of the SARS- CoV-2 virus. MicroGenDX laboratory is the first national laboratory to offer validated COVID-19 testing using saliva and sputum samples. The validation summary that exceeds the requirements of the FDA Emergency Use Authorization. Additionally, the test has been validated for both Nasopharyngeal (nasal) and Oropharyngeal (oral) swabs.

As indicated in a 2020 JAMA Study of Clinical Sputum Specimens for COVID, patients may have higher viral shedding patterns at different collection sites, with sputum collection being the most consistent sample method after bronchoalveolar lavage. While other laboratories and tests rely on nasal and throat swabs, MicroGenDX designed their COVID-19 collection method around sputum to more accurately identify the SARS- CoV-2 virus.

MicroGenDX planned the collection technique around saliva and sputum to prevent reliance on supply materials currently in shortage such as swabs and Viral Transport Media. The laboratory’s solution to the latter was to validate sterile saline as a viable transport media for testing.

“Our goal is to remove as many hurdles from people getting answers about COVID- 19,” continues Martin. “Given the challenges the healthcare system is having with procuring both swabs and transport media, we wanted to have another option for the healthcare provider to test patients.”

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

MicroGenDX runs its COVID-19 Rapid PCR Test at its diagnostic laboratory in Lubbock Texas with a 24-hour turnaround from time of sample receipt. The laboratory has begun running tests at a capacity of 5,000 COVID-19 samples a day and plans to increase that number to 10,000 per day in the near future.

MicroGenDX accepts samples from every state, joining the national response to COVID-19 at a time when hospital systems and drive-up testing facilities are hitting capacity and struggling to keep up with ever-increasing demand. The laboratory is currently bolstering its existing diagnostic teams to scale testing in accordance with the growing public need.

MicroGenDX is listed on the FDA Website as a resource laboratory for COVID-19 Testing as “Southwest Regional PCR dba MicroGenDX Laboratory.”

FDA Emergency Use Authorization Information

– In reporting information about this test, please be advised of the following:

– This test has been authorized by FDA under an EUA for use by authorized
Laboratories. This test has not been FDA cleared or approved.

– This test has been authorized only for the detection of nucleic acid from SARS- CoV-2, not for any other viruses or pathogens.

– This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for.

Source: HIT Consultant

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Boehringer Ingelheim Acquires Abexxa Biologics to Further Expand Its Research Efforts in Cancer Immunology and Novel Immunotherapeutic ApproachesBoehringer Ingelheim Acquires Abexxa Biologics to Further Expand Its Research Efforts in Cancer Immunology and Novel Immunotherapeutic Approaches
  • Fishawack continues to build best-in-class service offering with Dudnyk acquisitionFishawack continues to build best-in-class service offering with Dudnyk acquisition
  • New AI Tools Predict Parkinson’s Onset, Heart Attack Risk After Surgery, and More BriefsNew AI Tools Predict Parkinson’s Onset, Heart Attack Risk After Surgery, and More Briefs
  • Aledade Raises $64M for Value-Based Care Network of Physician-Led ACOsAledade Raises $64M for Value-Based Care Network of Physician-Led ACOs
  • 12 ways AI will revolutionize healthcare in the next year12 ways AI will revolutionize healthcare in the next year
  • Google Grants U Of Sydney $1M To Develop AI To Prevent Heart AttacksGoogle Grants U Of Sydney $1M To Develop AI To Prevent Heart Attacks
  • Former Kaiser Permanente CTO Mike Sutten Joins Innovaccer as Chief Digital OfficerFormer Kaiser Permanente CTO Mike Sutten Joins Innovaccer as Chief Digital Officer
  • When FDA Can Accept Greater Premarket Uncertainty For Medical DevicesWhen FDA Can Accept Greater Premarket Uncertainty For Medical Devices

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications